Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/232557METHOD OF MAKING COCOA BUTTER-DERIVED PRODUCTS CONTAINING CANNABINOIDS
WO 26.11.2020
Int.Class A23G 1/38
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
1Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
30Cocoa products, e.g. chocolate; Substitutes therefor
32characterised by the composition
36characterised by the fats used
38Cocoa butter substitutes
Appl.No PCT/CA2020/050692 Applicant CANOPY GROWTH CORPORATION Inventor GEILING, Ben
The present technology generally relates to methods of making cocoa butter-derived products that comprise cannabinoids. The present technology further generally relates to cocoa butter-derived products resulting from such methods.
2.WO/2020/233437USE OF DIKETONE COMPOUND IN PHOTODYNAMIC THERAPY OR DIAGNOSIS
WO 26.11.2020
Int.Class A61K 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
Appl.No PCT/CN2020/089628 Applicant BEIJING WHOLESOMETECH CO., LTD. Inventor JIAO, Ning
The present invention belongs to the technical field of medicine, and relates to use of a diketone compound in photodynamic therapy or diagnosis. In particular, the present invention relates to use of a compound as shown in formula (I), a pharmaceutically acceptable salt or ester thereof, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, metabolite forms thereof, or any combination or mixture thereof in the preparation of a medicament or a reagent. The medicament or the reagent is used for photodynamic therapy or photodynamic diagnosis of diseases, or is used for skin beauty by means of photodynamic therapy.
3.WO/2020/234277CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON S DISEASE
WO 26.11.2020
Int.Class A61K 31/4741
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4741condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
Appl.No PCT/EP2020/063918 Applicant H. LUNDBECK A/S Inventor JØRGENSEN, Morten
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
4.WO/2020/234817POLYMORPHIC FORMS OF APALUTAMIDE AND ITS PREPARATION THEREOF
WO 26.11.2020
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/IB2020/054815 Applicant LAURUS LABS LIMITED Inventor THAIMATTAM, Ram
The present invention relates to novel crystalline polymorphic forms of apalutamide. The present invention also relates to processes for preparation of amorphous form of apalutamide and pharmaceutical composition containing the same.
5.WO/2020/235587TANDOSPIRONE DERIVATIVE
WO 26.11.2020
Int.Class C07D 209/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56Ring systems containing three or more rings
58- or -condensed
724,7-Endo-alkylene-iso-indoles
76with oxygen atoms in positions 1 and 3
Appl.No PCT/JP2020/019911 Applicant NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA Inventor KONDO Takashi
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be used as an active ingredient of a drug for central nervous system diseases or as a candidate compound for a precursor of said active ingredient. In formula (1), R1, R2, and R3 each independently represent a substance selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkoxy group having 1-6 carbon atoms, and at least one of R1, R2, and R3 is a hydroxy group.
6.WO/2020/235727COMPOSITION FOR SKIN WHITENING COMPRISING FRACTION OF INULA HELENIUM EXTRACT OR COMPOUND ISOLATED THEREFROM AS ACTIVE INGREDIENT
WO 26.11.2020
Int.Class A61K 8/9789
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
96containing materials, or derivatives thereof, of undetermined constitution
97from algae, fungi, lichens or plants; from derivatives thereof
9783Angiosperms
9789Magnoliopsida
Appl.No PCT/KR2019/006211 Applicant SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION Inventor KIM, Yeong Shik
The present invention relates to a cosmetic composition for skin whitening comprising a hexane fraction of an Inula helenium extract, or an alantolactone or isoalantolactone compound isolated therefrom as an active ingredient. The fraction or compound according to the present invention inhibits melanin synthesis, and the compound of the present invention exhibits an effect of inhibiting mRNA or protein expression of a microphthalmia-associated transcription factor (MITF) which is a melanin synthesis promoting factor, tyrosinase, tyrosinase related protein 1, or tyrosinase related protein 2, and thus can be effectively used as a cosmetic composition for skin whitening, a pharmaceutical composition, or a functional health food.
7.WO/2020/235967COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING AUTOIMMUNE DISEASES
WO 26.11.2020
Int.Class A61K 31/569
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
568substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
569substituted in position 17 alpha, e.g. ethisterone
Appl.No PCT/KR2020/006714 Applicant INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Inventor LEE, Eun Jig
The present invention relates to a composition for preventing, alleviating or treating autoimmune diseases. The composition of the present invention not only suppresses the expression level of transcription factor proteins involved in induction of differentiation of orbital fibroblasts, but also significantly reduces the expression level of inflammatory cytokines, thereby very effectively inhibiting the differentiation of orbital fibroblasts. Thus, the composition of the present invention can be very effectively applied to the prevention, alleviation or treatment of autoimmune diseases, for example, Graves' orbitopathy.
8.WO/2020/236667METHODS OF TREATING CANCER
WO 26.11.2020
Int.Class A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
Appl.No PCT/US2020/033311 Applicant GB006, INC. Inventor DUPONT, Jakob
Disclosed herein are methods for treating cancer by administration to a patient in need thereof, an effective amount of (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene) methyl) furan-2-yl) benzoic acid or pharmaceutically acceptable salts thereof and pembrolizumab. In some embodiments, the choline salt Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene) methyl) furan-2-yl) benzoic acid is administered. In some embodiments, the patient has a solid tumor.
9.WO/2020/236907COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS
WO 26.11.2020
Int.Class A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
Appl.No PCT/US2020/033756 Applicant ALBERT EINSTEIN COLLEGE OF MEDICINE Inventor ALMO, Steven, C.
This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.
10.WO/2020/236947SOLID STATE FORMS
WO 26.11.2020
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No PCT/US2020/033831 Applicant AMGEN INC. Inventor CHAVES, Mary
The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous,hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.